Our most recent article to be published in Epilepsia focuses on the anti-seizure and disease-modifying effects of cannabidiol in a range of animal seizure and epilepsy models. The recent FDA approval of Epidiolex for the management of Lennox-Gastaut and Draves’s Syndrome are the target patient population for this new therapeutic approach to the use of cannabidiol (CBD) for epilepsy.